ArticleInflammatory bowel diseases2013
Increased risk of pneumocystis jiroveci pneumonia among patients with inflammatory bowel disease.
Article in Inflammatory bowel diseases, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 3 syntheses or guidelines pooled it, 89 citations in OpenAlex.
- Prophylaxis for Pneumocystis jirovecii pneumonia in patients with inflammatory bowel disease: A systematic review.Pharmacotherapy · 2022Pooled it
- Patients with Crohn's Disease Are More Likely to Remain on Biologics than Immunomodulators: A Meta-Analysis of Treatment Durability.Digestive diseases and sciences · 2015Pooled it
- Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients.The Cochrane database of systematic reviews · 2014Pooled it
- Risk Factors ofGut and liver · 2024Article
- Validity of claims-based diagnoses for infectious diseases common among immunocompromised patients in Japan.BMC infectious diseases · 2023Article
- Trends in the Epidemiology ofJournal of fungi (Basel, Switzerland) · 2023Review
- A Rare Case of Ulcerative Colitis with Severe Pneumocystis jirovecii Pneumonia and Cytomegalovirus Colitis: A Case Report and Literature Review.Internal medicine (Tokyo, Japan) · 2022Review
- Patients with inflammatory bowel disease are more hesitant about Coronavirus disease 2019 vaccination.Frontiers in medicine · 2022Article
- Home Infusions for Inflammatory Bowel Disease Are Safe: US Experience and Patient Perspectives.Crohn's & colitis 360 · 2021Article
- Management of Crohn Disease: A Review.JAMA · 2021Review
- Review
- A Case of COVID-19 andAmerican journal of respiratory and critical care medicine · 2020Article
- Serious and Opportunistic Infections in Elderly Patients With Inflammatory Bowel Disease.Gastroenterology & hepatology · 2019Article
- Risk Factors for Mortality inInflammatory intestinal diseases · 2019Article
- Increased Mortality Rates With Prolonged Corticosteroid Therapy When Compared With Antitumor Necrosis Factor-α-Directed Therapy for Inflammatory Bowel Disease.The American journal of gastroenterology · 2018Article
- Low Risk of Pneumonia From Pneumocystis jirovecii Infection in Patients With Inflammatory Bowel Disease Receiving Immune Suppression.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2017Article
- Detection of Pneumocystis jirovecii in oral wash from immunosuppressed patients as a diagnostic tool.PloS one · 2017Article
- The C-Type Lectin Mincle: Clues for a Role in Crohn's Disease Adjuvant Reaction.Frontiers in immunology · 2017Article
- Article
- Cost-effectiveness of Prophylaxis Against Pneumocystis jiroveci Pneumonia in Patients with Crohn's Disease.Digestive diseases and sciences · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
objectivesPatients with inflammatory bowel disease (IBD) may be at increased risk for pneumocystis jiroveci pneumonia (PCP). Our aims were (1) to determine the incidence and relative risk of PCP in IBD and (2) to describe medication exposures in patients with IBD with PCP.
methodsWe performed a retrospective cohort study and a case series using administrative data from IMS Health Inc, LifeLink Health Plan Claims Database. In the cohort, patients with IBD were matched to 4 individuals with no IBD claims. PCP risk was evaluated by incidence rate ratio and adjusted Cox proportional hazards modeling. The demographics and medication histories of the 38 cases of PCP in patients with IBD were extracted.
resultsThe cohort included 50,932 patients with Crohn's disease, 56,403 patients with ulcerative colitis, and 1269 patients with unspecified IBD; matched to 434,416 individuals without IBD. The crude incidence of PCP was higher in the IBD cohort (10.6/100,000) than in the non-IBD cohort (3.0/100,000). In the adjusted analyses, PCP risk was higher in the IBD versus non-IBD cohort (hazard ratio, 2.96; 95% confidence interval, 1.75-4.29), with the greatest risk in Crohn's disease compared with non-IBD (hazard ratio, 4.01; 95% confidence interval, 1.88-8.56). In the IBD case series of PCP cases (n = 38), the median age was 49 (interquartile range, 43-57). A total of 20 individuals (53%) were on corticosteroids alone or in combination with other immunosuppression.
conclusionsAlthough the overall incidence of PCP is low, patients with IBD are at increased risk. Patients with IBD with PCP are predominantly on corticosteroids alone or in combination before PCP diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.